Atlas Trials

TGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)

Clinical trial NCT05955391 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT05955391
Sponsor
Shenzhen TargetRx Co., Ltd.
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Non-small Cell Lung Cancer
Start date
2023-01-18
Primary completion
2024-12-29
Enrollment
164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.